for Human Health
Stroke and cardiac arrest affect millions of patients each year.
Re-establishment of blood flow to the brain—although life-saving—does not address the substantial impact on quality of life and healthcare costs associated with the resulting neuronal death and cognitive impairment. No drugs are available, leaving a tremendous market opportunity for a product that significantly reduces damage to the brain. Neurexis is directly addressing this unmet need.
The loss of blood flow to the brain can be caused by myriad events: Stroke, cardiac arrest/global cerebral ischemia, sickle cell anemia, congenital heart defects, high-risk vascular surgery, pre-existing coronary disease, etc. Paradoxically, the re-establishment of circulation triggers a cascade of proinflammatory events resulting in extensive nerve cell death, and significant cognitive and functional impairment. Stroke alone costs the United States an estimated $34B each year, including the cost of health care services, medicines to treat stroke, and missed days of work. Stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors age 65 and over. An FDA-approved neuroprotective peptide administered intravenously within 4 hours of the ischemic event as standard of care will greatly improve the quality of life of patients, as well as reduce the burden on domestic and international healthcare systems.
Neurexis is developing tatCN19o, an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.